BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Vaccine

• Publication date

  2015-06-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2015.04.049PMID 25917676
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CIITA and Its Dual Roles in MHC Gene Transcription

  2013cited by this paper
• Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis

  2013cited by this paper
• Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

  2012cited by this paper
• An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

  2010cited by this paper
• Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses

  2009cited by this paper
• RNA recognition and signal transduction by RIG‐I‐like receptors

  2009cited by this paper
• Construction, crystal structure and application of a recombinant protein that lacks the collagen‐like region of BclA from Bacillus anthracis spores

  2008cited by this paper
• Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.

  2008cited by this paper
• Enhancement of DNA Vaccine Potency through Coadministration of CIITA DNA with DNA Vaccines via Gene Gun1

  2008cited by this paper
• Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background

  2008cited by this paper
• Recombinant Exosporium Protein BclA of Bacillus anthracis Is Effective as a Booster for Mice Primed with Suboptimal Amounts of Protective Antigen

  2007cited by this paper
• Oral Administration of a Salmonella enterica-Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracis

  2006cited by this paper
• DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.

  2006cited by this paper
• Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.

  2006cited by this paper
• CARD games between virus and host get a new player.

  2006cited by this paper
• pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids.

  2006cited by this paper
• Synthetic bacterial lipopeptide analogs: structural requirements for adjuvanticity.

  2005cited by this paper
• IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction

  2005cited by this paper
• The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.

  2005cited by this paper
• Orientation within the Exosporium and Structural Stability of the Collagen-Like Glycoprotein BclA of Bacillus anthracis

  2005cited by this paper
• Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

  2004cited by this paper
• A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

  2004cited by this paper
• Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination.

  2004cited by this paper
• Identification of the Immunodominant Protein and Other Proteins of the Bacillus anthracis Exosporium

  2003cited by this paper
• A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection

  2002cited by this paper
• A collagen‐like surface glycoprotein is a structural component of the Bacillus anthracis exosporium

  2002cited by this paper
• Anthrax Spores Make an Essential Contribution to Vaccine Efficacy

  2002cited by this paper
• Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines.

  2002cited by this paper
• Introduction: anthrax history, disease and ecology.

  2002cited by this paper
• Peptide Vaccines and Peptide Libraries

  2001cited by this paper
• Anthrax Toxin

  2001cited by this paper
• Protection against Anthrax Lethal Toxin Challenge by Genetic Immunization with a Plasmid Encoding the Lethal Factor Protein

  2001cited by this paper
• In vitro correlate of immunity in a rabbit model of inhalational anthrax.

  2001cited by this paper
• DNA Vaccination against Tuberculosis: Expression of a Ubiquitin-Conjugated Tuberculosis Protein Enhances Antimycobacterial Immunity

  2000cited by this paper
• Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells.

  1999cited by this paper
• Immunogenicity of DNA Vaccines Expressing Tuberculosis Proteins Fused to Tissue Plasminogen Activator Signal Sequences

  1999cited by this paper
• Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization.

  1997cited by this paper
• Development of novel vaccines against anthrax in man.

  1996cited by this paper
• Ubiquitin as a degradation signal.

  1992cited by this paper
• Anthrax vaccines: past, present and future.

  1991cited by this paper
• Class II MHC molecules can use the endogenous pathway of antigen presentation

  1990cited by this paper
• Identification of two lysosomal membrane glycoproteins

  1985cited by this paper
• Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid.

  1985cited by this paper
• Evidence for plasmid-mediated toxin production in Bacillus anthracis

  1983cited by this paper
• An evaluation of

  1983cited by this paper
• The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo.

  1955cited by this paper

• ANTHRAX: LIFE CYCLE, MECHANISMS OF PATHOGENESIS AND PROSPECTS IN THE DEVELOPMENT OF VETERINARY VACCINES (review)

  2021cites this paper
• Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes

  2020cites this paper
• Anthrax prevention through vaccine and post-exposure therapy

  2020cites this paper
• Immunogenicity and Protective Efficacy of a Non-Living Anthrax Vaccine versus a Live Spore Vaccine with Simultaneous Penicillin-G Treatment in Cattle

  2020cites this paper
• Vaccines against anthrax based on recombinant protective antigen: problems and solutions

  2019cites this paper
• 11 – Anthrax Vaccines*

  2018cites this paper
• A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis

  2018cites this paper
• Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model

  2018cites this paper
• Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions

  2017cites this paper
• Comparative studies on the immunogenicity of the live spore anthrax vaccine versus non-living vaccine candidates in goats and protective capacity of immune sera in mice

  2016cites this paper
• The Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected Host

  2015cites this paper